Cyclic AMP‐dependent protein kinase and D1 dopamine receptors regulate diacylglycerol lipase‐α and synaptic 2‐arachidonoyl glycerol signaling

Brain endocannabinoids serve as retrograde neurotransmitters, being synthesized in post‐synaptic neurons “on demand” and released to bind pre‐synaptic cannabinoid receptors and suppress glutamatergic or GABAergic transmission. The most abundant brain endocannabinoid, 2 arachidonoyl glycerol (2‐AG),...

Full description

Saved in:
Bibliographic Details
Published inJournal of neurochemistry Vol. 153; no. 3; pp. 334 - 345
Main Authors Shonesy, Brian C., Stephenson, Jason R., Marks, Christian R., Colbran, Roger J.
Format Journal Article
LanguageEnglish
Published England Blackwell Publishing Ltd 01.05.2020
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Brain endocannabinoids serve as retrograde neurotransmitters, being synthesized in post‐synaptic neurons “on demand” and released to bind pre‐synaptic cannabinoid receptors and suppress glutamatergic or GABAergic transmission. The most abundant brain endocannabinoid, 2 arachidonoyl glycerol (2‐AG), is primarily synthesized by diacylglycerol lipase‐α (DGLα), which is activated by poorly understood mechanisms in response to calcium influx following post‐synaptic depolarization and/or the activation of Gq‐coupled group 1 metabotropic glutamate receptors. However, the impact of other neurotransmitters and their downstream signaling pathways on synaptic 2‐AG signaling has not been intensively studied. Here, we found that DGLα activity in membrane fractions from transfected HEK293T cells was significantly increased by in vitro phosphorylation using cyclic AMP‐dependent protein kinase (PKA). Moreover, PKA directly phosphorylated DGLα at Ser798 in vitro. Elevation of cAMP levels in HEK293 cells expressing DGLα increased Ser798 phosphorylation, as detected using a phospho‐Ser798‐specific antibody, and enhanced DGLα activity; this in situ enhancement of DGLα activity was prevented by mutation of Ser798 to Ala. We investigated the impact of PKA on synaptic 2‐AG mobilization in mouse striatal slices by manipulating D1‐dopamine receptor (D1R) signaling and assessing depolarization‐induced suppression of excitation, a DGLα‐ and 2‐AG‐dependent form of short‐term synaptic depression. The magnitude of depolarization‐enhanced suppression of excitation in direct pathway medium spiny neurons was increased by pre‐incubation with a D1R agonist, and this enhancement was blocked by post‐synaptic inhibition of PKA. Taken together, these findings provide new molecular insights into the complex mechanisms regulating synaptic endocannabinoid signaling. Post‐synaptic synthesis of a major brain endocannabinoid, 2‐arachidonoyl glycerol (2‐AG), from diacylglycerol (DAG) by diacylglycerol lipase‐α (DGLα) is stimulated by L‐type voltage‐gated calcium channels (LTCC) and/or metabotropic glutamate receptors (mGluR1/5). Shonesy et al show that cyclic AMP‐dependent protein kinase (PKA) phosphorylates Ser798 in DGLα to increase activity. Their data indicate that D1‐dopamine receptors (D1R) stimulate adenylyl cyclase (Ca2+‐AC) and PKA to enhance synaptic 2‐AG production by DGLα and short‐term depression of glutamatergic transmission, which depends on pre‐synaptic endocannabinoid 1 receptors (CB1R). Ca2+/calmodulin‐dependent protein kinase II (CaMKII) was previously shown to phosphorylate distinct sites in DGLα to restrain synaptic 2‐AG synthesis. Read the Editorial Highlight for this article on https://doi.org/10.1111/jnc.14977
Bibliography:Funding information
This work was supported by the National Institutes of Health (K01 MH107765 to B.C.S., T32‐MH065215 to J.R.S., F31‐MH109196 and T32‐DK07563 to C.R.M., R01‐NS078291 to R.J.C.), the American Heart Association (15PRE25110020 to C.R.M), and Vanderbilt University. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health or other funding agencies. Endocannabinoid measurements were conducted at the Vanderbilt Mass Spectrometry Research Center Facility with an instrument purchased with support from the National Institutes of Health (Grant No. S10 OD017997). The authors report no significant biomedical financial interests or potential conflicts of interest.
BCS: directed the study, designed and performed most of experiments, analyzed and interpreted the data, wrote the first draft of the manuscript, and edited the final manuscript.
JRS: conducted and analyzed some of the electrophysiological studies.
All authors have read and approve of the final manuscript.
RJC: contributed to the conceptual design of the project and the experiments, contributed to the data interpretation and wrote the final manuscript.
Author contributions
CRM: significantly contributed to DGLα activity assays.
ISSN:0022-3042
1471-4159
DOI:10.1111/jnc.14972